

LIPOXIN MEDIATED NEUROPROTECTION

Tech ID: 27404 / UC Case 2017-109-0

PATENT STATUS

| Country | Type | Number | Dated | Case |
|--------------------------|-----------------------|------------|------------|----------|
| United States Of America | Issued Patent | 11,439,615 | 09/13/2022 | 2017-109 |
| Canada | Published Application | | | 2017-109 |

Additional Patent Pending

BRIEF DESCRIPTION

This is small molecule neuroprotective activity secreted from resting astrocytes in the inner retina, where neighboring retinal ganglion cell neurons (RGCs) are vulnerable to irreversible damage in the neurodegenerative disease glaucoma.

SUGGESTED USES

Therapeutic treatment with LXB₄ is efficacious in both pathological and functional measures in a chronic glaucoma model. Together, these results indicate a novel resident neuroprotective mechanism for LXB₄ that can become deficient following neuronal injury. Restoration of this balance suggests a therapeutic potential.

ADVANTAGES

The role and regulation of labile small molecule factors in neuroinflammation and neurodegeneration is not well understood. This small molecule has neuroprotective activity secreted from resting astrocytes in the inner retina, where neighboring retinal ganglion cell neurons (RGCs) are vulnerable to irreversible damage in the neurodegenerative disease glaucoma.

RELATED MATERIALS

CONTACT

Craig K. Kennedy
craig.kennedy@berkeley.edu
 tel: .



INVENTORS

» Flanagan, John G.

OTHER INFORMATION

KEYWORDS

Retinal, Glaucoma

CATEGORIZED AS

» **Medical**
 » Disease: Ophthalmology
 and Optometry

RELATED CASES

2017-109-0